{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:01:01Z","timestamp":1790708461774,"version":"4.1.0"},"reference-count":188,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The word \u201cpsychedelic\u201d (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT\/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA (3,4-methylenedioxymethamphetamine) and psilocybin have had significant value as an entheogen in spiritual, religious (shamanic) and sociocultural rituals in Central and South American cultures for thousands of years. In the 1960s, the globalization of these drugs and their subsequent spread outside of their indigenous, old-world cultures, led to the subsequent implementation of strict drug control laws in many Western countries. Even today, psychedelics are still classified as Schedule I drugs, resulting in a still lingering negative stigmatization\/perception, vilification, and ultimate criminalization of psychedelics. This controversy still lingers and still limits scientific research and full medical acceptance. For many years up until recently, the spiritual, religious and medicinal value of these drugs could not be explored in a scientific context. More recently, a second wave of psychedelic research is now focusing on psychedelics as neuropharmaceuticals to treat alcohol and tobacco addiction, general mood and anxiety disorders and cancer-related depression. There is now a vast array of promising evidence-based data to confirm the years of anecdotal evidence of the medicinal values of psychedelics. Natural therapeutic alternatives such as psychedelic drugs may provide a safe and efficacious alternate to conventional drugs used to treat mood and anxiety disorders. In a Western context in particular, psychedelic drugs as therapeutic agents for mood and anxiety disorders are becoming increasingly of interest amidst increasing rates of such disorders globally, changing social constructions, the implementation of government regulations and increasing investment opportunities, that ultimately allow for the scientific study to generate evidenced-based data. Alternative psychotherapeutic interventions are gaining interest also, because of their low physiological toxicity, relatively low abuse potential, safe psychological effects, and no associated persisting adverse physiological or psychological effects during and after use. On the other hand, conventional psychotic drugs and anti-depressants are becoming less favorable because of their adverse side effects. Psychedelic neuropharmaceutical interventions may with medical oversight be the solution to conventional psychiatric disorders such as depression and anxiety, and an alternative to conventional psychiatric treatment options. This paper will review the therapeutic potential of psychedelic drugs as alternative therapeutic options for mood and anxiety disorders in a controlled, clinical setting, where the chances of adverse psychological episodes occurring are mitigated.<\/jats:p>","DOI":"10.3390\/molecules27082520","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T23:07:16Z","timestamp":1649891236000},"page":"2520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders"],"prefix":"10.3390","volume":"27","author":[{"given":"Henry","family":"Lowe","sequence":"first","affiliation":[{"name":"Biotech Research and Development Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA"},{"name":"Flavocure Biotech Inc., Baltimore, MD 21202, USA"},{"name":"Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-6192","authenticated-orcid":false,"given":"Ngeh","family":"Toyang","sequence":"additional","affiliation":[{"name":"Biotech Research and Development Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA"},{"name":"Flavocure Biotech Inc., Baltimore, MD 21202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Steele","sequence":"additional","affiliation":[{"name":"Biotech Research and Development Institute, University of the West Indies, Mona 99999, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grant","sequence":"additional","affiliation":[{"name":"Biotech Research and Development Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"The Psyence Group, Toronto, ON M5J 2J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amza","family":"Ali","sequence":"additional","affiliation":[{"name":"Biotech Research and Development Institute, University of the West Indies, Mona 99999, Jamaica"},{"name":"The Psyence Group, Toronto, ON M5J 2J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gordon","sequence":"additional","affiliation":[{"name":"Caribbean School of Medical Sciences, Kingston 99999, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Ngwa","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"},{"name":"Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_2","unstructured":"Kelley, A. (2021, February 18). Americans are Taking More Anti-Anxiety Medication and Antidepressants during CORONAVIRUS Pandemic: Report. Available online: https:\/\/thehill.com\/changing-america\/well-being\/mental-health\/493125-increase-in-anti-anxiety-medication-antidepressants."},{"key":"ref_3","unstructured":"Harvard Health Publishing (2021, February 18). What Are the Real Risks of Antidepressants?. Available online: https:\/\/www.health.harvard.edu\/mind-and-mood\/what-are-the-real-risks-of-antidepressants."},{"key":"ref_4","unstructured":"Mayo Clinic Staff (2021, February 18). The Most Commonly Prescribed Type of Antidepressant. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/depression\/in-depth\/ssris\/art-20044825."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","article-title":"Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids","volume":"102","author":"Gable","year":"2007","journal-title":"Addiction"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential Therapeutic Effects of Psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of Psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_8","unstructured":"Oliveira e Souza, R. (2021, January 16). COVID-19 Pandemic Exacerbates Suicide Risk Factors. Available online: https:\/\/www.paho.org\/en\/news\/10-9-2020-covid-19-pandemic-exacerbates-suicide-risk-factors."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2045125316676092","article-title":"Role of Psilocybin in the treatment of depression","volume":"7","author":"Mahapatra","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0376-8716(98)00129-X","article-title":"Do hallucinogens cause residual neuropsychological toxicity?","volume":"53","author":"Halpern","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"ref_12","unstructured":"Lim, A. (2021, February 18). Psychedelics as Antidepressants. Available online: https:\/\/www.scientificamerican.com\/article\/psychedelics-as-antidepressants\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","article-title":"Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis","volume":"180","author":"Thisted","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0024-3205(72)90153-1","article-title":"Lysergic acid diethylamide and serotonin: Direct actions on serotonin-containing neurons in rat brain","volume":"11","author":"Aghajanian","year":"1972","journal-title":"Life Sci."},{"key":"ref_16","unstructured":"(2021, February 16). National Center for Biotechnology Information PubChem Compound Summary for CID 1150, Tryptamine, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tryptamine."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_18","first-page":"120","article-title":"A High-Resolution In Vivo Atlas of the Human Brain\u2019s Serotonin System","volume":"37","author":"Beliveau","year":"2017","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_20","first-page":"157","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"ref_21","unstructured":"Frazer, A., and Hensler, J.G. (2021, March 09). Serotonin Involvement in Physiological Function and Behavior. Basic Neurochemistry: Molecular, Cellular and Medical Aspects, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27940\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"pe12","DOI":"10.1126\/scisignal.261pe12","article-title":"When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor","volume":"2","author":"Su","year":"2009","journal-title":"Sci. Signal."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/164_2018_107","article-title":"Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action","volume":"252","author":"Canal","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/157488707779318107","article-title":"The potential of trace amines and their receptors for treating neurological and psychiatric diseases","volume":"2","author":"Berry","year":"2007","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","article-title":"Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges","volume":"180","author":"Berry","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.117.015305","article-title":"Trace Amines and Their Receptors","volume":"70","author":"Gainetdinov","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.115.229765","article-title":"In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1","volume":"357","author":"Simmler","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1098\/rstb.2012.0190","article-title":"The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms","volume":"367","author":"Albert","year":"2012","journal-title":"Philos. Trans. R. Soc. London Ser. B Biol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., and Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules, 26.","DOI":"10.3390\/molecules26102948"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic Ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial","volume":"49","author":"Barreto","year":"2019","journal-title":"Psychol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Labate, B., and Cavnar, C. (2014). The Therapeutic Potentials of Ayahuasca in the Treatment of Depression. The Therapeutic Use of Ayahuasca, Springer.","DOI":"10.1007\/978-3-642-40426-9"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/0101-60830000000149","article-title":"Long-term effects of Ayahuasca in patients with recurrent depression: A 5-year qualitative follow-up","volume":"45","author":"Sanches","year":"2018","journal-title":"Arch. Clin. Psychiatry (S\u00e3o Paulo)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of Ayahuasca, Psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years","volume":"6","author":"Crippa","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of Ayahuasca in patients with recurrent depression: A preliminary report","volume":"37","author":"Sanches","year":"2015","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1176\/ajp.126.4.481","article-title":"LSD in the treatment of alcoholism","volume":"126","author":"Johnson","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.15288\/qjsa.1964.25.333","article-title":"The Efficacy of LSD in the Treatment of Alcoholism","volume":"25","author":"Smart","year":"1964","journal-title":"Q. J. Stud. Alcohol"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0021-9681(71)90050-6","article-title":"LSD and alcoholism: A clinical study of treatment efficacy","volume":"24","author":"Visotsky","year":"1971","journal-title":"J. Chronic Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archpsyc.1968.01740100124021","article-title":"Lysergic Acid Diethylamide (LSD) in the Treatment of Alcoholism","volume":"19","author":"Dahlberg","year":"1968","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_42","first-page":"10","article-title":"The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics","volume":"4","author":"Simmons","year":"1972","journal-title":"Behav. Neuropsychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/070674376100600407","article-title":"The use of L.S.D. 25 (D-lysergic acid diethylamide) in the treatment of the sexual perversions","volume":"6","author":"Ball","year":"1961","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13638490601106277","article-title":"Flashback to the 1960s: LSD in the treatment of autism","volume":"10","author":"Sigafoos","year":"2007","journal-title":"Dev. Neurorehabilit."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zamaria, J.A. (2016). A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects. NeuroQuantology, 14.","DOI":"10.14704\/nq.2016.14.2.943"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e230109","DOI":"10.1136\/bcr-2019-230109","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: Preliminary data on the first four participants","volume":"12","author":"Sessa","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_48","unstructured":"Zarley, B.D. (2021, March 10). First-of-Its-Kind Pilot Study Uses MDMA for Alcohol Addiction. Available online: https:\/\/www.freethink.com\/articles\/mdma-for-alcohol-addiction."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial","volume":"32","author":"Grigsby","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","article-title":"5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety","volume":"45","author":"Davis","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fnmol.2018.00312","article-title":"A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus","volume":"11","author":"Moulin","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/02791072.2020.1737763","article-title":"Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects","volume":"52","author":"Lancelotta","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"32067","DOI":"10.1021\/acsomega.0c05099","article-title":"Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use","volume":"5","author":"Sherwood","year":"2020","journal-title":"ACS Omega"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"109735","DOI":"10.1016\/j.pnpbp.2019.109735","article-title":"Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis","volume":"96","author":"Bahji","year":"2020","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dos Santos, R.G., Os\u00f3rio, F.L., Rocha, J.M., Rossi, G.N., Bouso, J.C., Rodrigues, L.S., de Oliveira Silveira, G., Yonamine, M., and Hallak, J. (2021). Ayahuasca Improves Self-perception of Speech Performance in Subjects with Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial. J. Clin. Psychopharmacol.","DOI":"10.1097\/JCP.0000000000001428"},{"key":"ref_57","unstructured":"Leonard, J. (2021, February 07). Ayahuasca: What It Is, Effects, and Usage (1182927539 885508185 Warwick, K.W., Ed.). Available online: https:\/\/www.medicalnewstoday.com\/articles\/Ayahuasca."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix","volume":"29","author":"Eisner","year":"1997","journal-title":"J. Psychoact. Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.drugpo.2006.11.001","article-title":"The globalization of Ayahuasca: Harm reduction or benefit maximization?","volume":"19","author":"Tupper","year":"2008","journal-title":"Int. J. Drug Policy"},{"key":"ref_60","unstructured":"Scaccia, A. (2021, March 10). What Psychedelics Really Do to Your Brain. Rolling Stone. Available online: https:\/\/www.rollingstone.com\/culture\/culture-news\/what-psychedelics-really-do-to-your-brain-112948\/."},{"key":"ref_61","unstructured":"Stafford, P.G., and Bigwood, J. (2013). Psychedelics Encyclopedia, Ronin Publishing."},{"key":"ref_62","unstructured":"Inaba, D., and Cohen, W.E. (2014). Uppers, Downers, All Arounders: Physical and Mental Effects of Psychoactive Drugs, CNS Productions. [7th ed.]."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","article-title":"Psilocybin: From ancient magic to modern medicine","volume":"73","author":"Nichols","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_64","unstructured":"Usdin, E., Hamburg, D.A., and Barchassca, J.D. (1977). Some general thoughts about endogenous psychotogens. Neuroregulators and Psychiatric Disorders, Oxford University Press."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.175.4028.1365","article-title":"Psychotomimetic N-methylated tryptamines: Formation in brain in vivo and in vitro","volume":"175","author":"Saavedra","year":"1972","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1192\/bjp.137.3.236","article-title":"A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients","volume":"137","author":"Checkley","year":"1980","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9333","DOI":"10.1038\/s41598-019-45812-w","article-title":"Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain","volume":"9","author":"Dean","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/ajp.133.2.203","article-title":"The psychedelic model of schizophrenia: The case of N,N-dimethyltryptamine","volume":"133","author":"Gillin","year":"1976","journal-title":"Am. J. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.mehy.2004.11.005","article-title":"Endogenous psychoactive tryptamines reconsidered: An anxiolytic role for dimethyltryptamine","volume":"64","author":"Jacob","year":"2005","journal-title":"Med. Hypotheses"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archpsyc.1979.01780060034003","article-title":"Increased excretion of dimethyltryptamine and certain features of psychosis: A possible association","volume":"36","author":"Murray","year":"1979","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-8741(98)00163-9","article-title":"Ayahoasca: An experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia","volume":"65","author":"Pomilio","year":"1999","journal-title":"J. Ethnopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00702-014-1329-5","article-title":"On the transmethylation hypothesis: Stress, N,N-dimethyltryptamine, and positive symptoms of psychosis","volume":"122","author":"Grammenos","year":"2015","journal-title":"J. Neural Transm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0166-2236(84)80276-3","article-title":"The transmethylation hypotheses of schizophrenia re-evaluated","volume":"7","author":"Smythies","year":"1984","journal-title":"Trends Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.12688\/f1000research.10094.1","article-title":"Understanding the role of serotonin in psychiatric diseases","volume":"6","author":"Marazziti","year":"2017","journal-title":"F1000Research"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav. Brain Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers","volume":"38","author":"Heekeren","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0000000000000078","article-title":"N,N-Dimethyltryptamine-Induced Psychosis","volume":"38","author":"Paterson","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_79","unstructured":"(2021, February 07). Dmt. Available online: https:\/\/www.release.org.uk\/drugs\/dmt\/pharmacology."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of Ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2016.01.005","article-title":"Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine","volume":"143","author":"Halberstadt","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_82","unstructured":"(2021, February 07). An Option if Other Antidepressants Haven\u2019t Helped. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/depression\/in-depth\/maois\/art-20043992."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fnins.2016.00423","article-title":"The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells","volume":"10","author":"Szabo","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fphar.2016.00035","article-title":"The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization","volume":"7","author":"Frecska","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fphar.2018.00330","article-title":"Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process","volume":"9","author":"Inserra","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2012.01.030","article-title":"The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements","volume":"682","author":"Pal","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-Dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res. Bull."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.9740\/mhc.2017.01.039","article-title":"Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?","volume":"7","author":"Malcolm","year":"2018","journal-title":"Ment. Health Clin."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1590\/1516-4446-2020-0884","article-title":"The pharmacological interaction of compounds in Ayahuasca: A systematic review","volume":"42","author":"Ruffell","year":"2020","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11207","DOI":"10.1073\/pnas.1902174116","article-title":"Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America","volume":"116","author":"Miller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fnbeh.2017.00139","article-title":"Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish","volume":"11","author":"Savoldi","year":"2017","journal-title":"Front. Behav. Neurosci."},{"key":"ref_92","unstructured":"Labate, B.C., and Macrae, E. (2020). Ayahuasca, Ritual and Religion in Brazil, CRC Press."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.fct.2009.12.019","article-title":"\u03b2-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)","volume":"48","author":"Herraiz","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1038\/s41598-017-05407-9","article-title":"The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro","volume":"7","author":"Feilding","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41598-020-61169-x","article-title":"Effects of Ayahuasca on mental health and quality of life in na\u00efve users: A longitudinal and cross-sectional study combination","volume":"10","author":"Ona","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2004.03.002","article-title":"Clinical investigations of the therapeutic potential of Ayahuasca: Rationale and regulatory challenges","volume":"102","author":"McKenna","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1139\/cjr31-097","article-title":"A synthesis of the methyltryptamines and some derivatives","volume":"5","author":"Manske","year":"1931","journal-title":"Can. J. Res."},{"key":"ref_98","unstructured":"Bigwood, J., and Ott, J. (2021, March 04). GWU Event on Colombia. for Wola if You Need Higher Resolution, Please e-mail Me, and I Will Send Them in Hi-res. Available online: https:\/\/web.archive.org\/web\/20060127003553\/."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant Effects of a Single Dose of Ayahuasca in Patients with Recurrent Depression: A SPECT Study","volume":"36","author":"Sanches","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jep.2007.04.012","article-title":"Effects of Ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members","volume":"112","author":"Santos","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00213-018-4988-3","article-title":"Sub-acute and long-term effects of Ayahuasca on affect and cognitive thinking style and their association with ego dissolution","volume":"235","author":"Uthaug","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fphar.2018.00224","article-title":"Four Weekly Ayahuasca Sessions Lead to Increases in \u201cAcceptance\u201d Capacities: A Comparison Study with a Standard 8-Week Mindfulness Training Program","volume":"9","author":"Soler","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fpsyt.2018.00185","article-title":"Cortisol Modulation by Ayahuasca in Patients with Treatment Resistant Depression and Healthy Controls","volume":"9","author":"Silva","year":"2018","journal-title":"Front. Psychiatry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2016.1260189","article-title":"Effects of the Natural \u03b2-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies","volume":"49","author":"Hallak","year":"2017","journal-title":"J. Psychoact. Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/02791072.2013.873157","article-title":"Therapeutic effects of ritual Ayahuasca use in the treatment of substance dependence\u2014qualitative results","volume":"46","author":"Verres","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Palhano-Fontes, F., Andrade, K.C., Tofoli, L.F., Santos, A.C., Crippa, J.A.S., Hallak, J.E.C., Ribeiro, S., and de Araujo, D.B. (2015). The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118143"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hbm.20531","article-title":"Functional connectivity of default mode network components: Correlation, anticorrelation, and causality","volume":"30","author":"Uddin","year":"2009","journal-title":"Hum. Brain Mapp."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1440.011","article-title":"The brain\u2019s default network: Anatomy, function, and relevance to disease","volume":"1124","author":"Buckner","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neulet.2010.10.056","article-title":"Increased default mode network connectivity associated with meditation","volume":"487","author":"Jang","year":"2011","journal-title":"Neurosci. Lett."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hbm.20537","article-title":"Persistent default-mode network connectivity during light sedation","volume":"29","author":"Greicius","year":"2008","journal-title":"Hum. Brain Mapp."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11376","DOI":"10.1073\/pnas.0901435106","article-title":"Decoupling of the brain\u2019s default mode network during deep sleep","volume":"106","author":"Horovitz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuroimage.2011.04.020","article-title":"Brain functional integration decreases during propofol-induced loss of consciousness","volume":"57","author":"Schrouff","year":"2011","journal-title":"NeuroImage"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with Psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional connectivity measures after Psilocybin inform a novel hypothesis of early psychosis","volume":"39","author":"Leech","year":"2013","journal-title":"Schizophr. Bull."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.1131295","article-title":"Wandering minds: The default network and stimulus-independent thought","volume":"315","author":"Mason","year":"2007","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"20254","DOI":"10.1073\/pnas.1112029108","article-title":"Meditation experience is associated with differences in default mode network activity and connectivity","volume":"108","author":"Brewer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/cercor\/bhq295","article-title":"Development of the brain\u2019s default mode network from wakefulness to slow wave sleep","volume":"21","author":"Wehrle","year":"2011","journal-title":"Cereb. Cortex"},{"key":"ref_120","unstructured":"Barrett, J. (2021, February 08). Ayahuasca Tourism: The Commercialization of Culture. Available online: https:\/\/worldfootprints.com\/Ayahuasca-tourism-the-commercialization-of-culture\/."},{"key":"ref_121","unstructured":"Draven, J. (2021, February 08). Hot Topic: Is Ayahuasca Tourism a Bad Trip?. Available online: https:\/\/www.nationalgeographic.co.uk\/travel\/2017\/03\/hot-topic-Ayahuasca-tourism-bad-trip."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/02791072.2015.1094590","article-title":"Ayahuasca Tourism: Participants in Shamanic Rituals and their Personality Styles, Motivation, Benefits and Risks","volume":"47","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"ref_123","unstructured":"Hill, D. (2021, February 09). Peru\u2019s Ayahuasca Industry Booms as Westerners Search for Alternative Healing. Available online: https:\/\/www.theguardian.com\/travel\/2016\/jun\/07\/peru-Ayahuasca-drink-boom-amazon-spirituality-healing."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"Ee126","DOI":"10.1111\/csp2.126","article-title":"The Ayahuasca tourism boom: An undervalued demand driver for jaguar body parts?","volume":"1","author":"Braczkowski","year":"2019","journal-title":"Conserv. Sci. Pract."},{"key":"ref_125","unstructured":"Crisafulli, A. (2021, February 09). Ayahuasca Tourism: Shamans, Charlatans AND Thousand-Dollar Retreats. Available online: https:\/\/www.vergemagazine.com\/travel-intelligence\/beyond-the-guidebook\/2495-is-Ayahuasca-tourism-safe-and-ethical.html."},{"key":"ref_126","unstructured":"Babe, A. (2021, February 08). Ayahuasca Tourism is Ripping off Indigenous Amazonians. Available online: https:\/\/www.vice.com\/en\/article\/qbn8vq\/Ayahuasca-tourism-is-ripping-off-indigenous-amazonians."},{"key":"ref_127","unstructured":"Vaughn, C. (2021, February 09). Ayahuasca Ceremonies and Tourism Return to Costa Rica. Available online: https:\/\/news.co.cr\/Ayahuasca-ceremonies-and-tourism-return-to-costa-rica\/82489\/."},{"key":"ref_128","unstructured":"Matthews, K. (2021, February 09). Visiting Brazil for an Ayahuasca Ceremony. Available online: https:\/\/thetravelmanuel.com\/visiting-brazil-for-an-Ayahuasca-ceremony\/."},{"key":"ref_129","unstructured":"Fraser, B. (2021, February 09). The Perils and Privileges of an Amazonian Hallucinogen. Available online: https:\/\/www.sapiens.org\/culture\/Ayahuasca-tourism-amazon\/."},{"key":"ref_130","unstructured":"(2021, February 09). Om Spirit. Ayahuasca Retreat Sacred Valley Tribe. Available online: https:\/\/omspirit.net\/retrets-centers\/ayahuasca-retreat-sacred-valley-tribe\/."},{"key":"ref_131","unstructured":"Amor, B. (2021, February 09). Ayahuasca is the Latest TRENDY Tonic for White People Problems. Available online: https:\/\/www.bitchmedia.org\/article\/heart-of-whiteness-spiritual-tourism-colonization-Ayahuasca."},{"key":"ref_132","unstructured":"Hay, M. (2021, February 09). The Colonization of the Ayahuasca Experience. JSTOR Daily. Available online: https:\/\/daily.jstor.org\/the-colonization-of-the-ayahuasca-experience\/."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00213-006-0566-1","article-title":"The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats","volume":"189","author":"Ruiz","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ray, T.S. (2010). Psychedelics and the human receptorome. PLoS ONE, 5.","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Malaca, S., Lo Faro, A.F., Tamborra, A., Pichini, S., Busard\u00f2, F.P., and Huestis, M.A. (2020). Toxicology and Analysis of Psychoactive Tryptamines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239279"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1246\/bcsj.11.221","article-title":"\u00dcber die synthese des bufotenin-methyl-\u00e4thers (5-methoxy-n-dimethyl-tryptamin) und bufotenins (synthesen in der indol-gruppe. xv)","volume":"11","author":"Hoshino","year":"1936","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/jo01091a032","article-title":"Indole alkaloids of acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis","volume":"24","author":"Pachter","year":"1959","journal-title":"J. Org. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-8741(94)90051-5","article-title":"Bufo alvarius: A potent hallucinogen of animal origin","volume":"41","author":"Weil","year":"1994","journal-title":"J. Ethnopharmacol."},{"key":"ref_140","unstructured":"(2021, February 05). Guide to 5-MeO-DMT-EXPERIENCE, BENEFITS, & Side Effects. Available online: https:\/\/thethirdwave.co\/psychedelics\/5-meo-dmt\/."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","article-title":"A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms","volume":"236","author":"Uthaug","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","article-title":"The hallucinogenic world of tryptamines: An updated review","volume":"89","author":"Carvalho","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-008-1247-z","article-title":"Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors","volume":"201","author":"Halberstadt","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1124\/dmd.112.050724","article-title":"Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status","volume":"41","author":"Jiang","year":"2013","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_145","unstructured":"Gale, E. (2021, March 10). Bufo Alvarius-Colorado River Toad Sonoran Desert Toad. Available online: https:\/\/www.erowid.org\/archive\/sonoran_desert_toad\/deeptoad.htm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02866491","article-title":"Hallucinogenic snuff from Northwestern Argentina: Microscopical identification of anadenanthera colubrina var. cebil (fabaceae) in powdered archaeological material","volume":"53","author":"Pochettino","year":"1999","journal-title":"Econ. Bot."},{"key":"ref_147","first-page":"410","article-title":"Usos rituales de la semilla de Anadenanthera sp entre los ind\u00edgenas sudamericanos [Ritual use of Anadenanthera seeds among South America natives]","volume":"22","year":"2007","journal-title":"Neurologia"},{"key":"ref_148","unstructured":"Schultes, R.E. (2021, February 05). The Plant Kingdom and Hallucinogens (Part II). Available online: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/bulletin\/bulletin_1969-01-01_4_page004.html."},{"key":"ref_149","unstructured":"(2021, March 10). Pipeline: GH Research. GH Research Limited (n.d.). Available online: https:\/\/www.ghres.com\/pipeline."},{"key":"ref_150","unstructured":"(2021, March 10). Lysergide (LSD) drug profile. European Monitoring Centre for Drugs and Drug Addiction. Available online: https:\/\/www.emcdda.europa.eu\/publications\/drug-profiles\/lsd_en."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and Psilocybin for the management of patients with persistent pain: A potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/dta.2222","article-title":"Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)","volume":"10","author":"Brandt","year":"2018","journal-title":"Drug Test. Anal."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00213-018-5055-9","article-title":"Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)","volume":"236","author":"Halberstadt","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","article-title":"LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors","volume":"118","author":"Watts","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1021\/jm00147a022","article-title":"Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives","volume":"28","author":"Hoffman","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0091-3057(94)90172-4","article-title":"Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives","volume":"47","author":"Huang","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0022-3999(64)90081-9","article-title":"Lysergic acid (LSD 25) and ritalin in the treatment of neurosis","volume":"8","author":"Davies","year":"1964","journal-title":"J. Psychosom. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2045125316640440","article-title":"Lysergic acid diethylamide: A drug of \u2018use\u2019?","volume":"6","author":"Das","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.15288\/qjsa.1971.32.589","article-title":"Book Reviews-LSD and alcoholism; a clinical study of treatment efficacy","volume":"32","author":"Jordy","year":"1971","journal-title":"Q. J. Stud. Alcohol"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2307\/3952791","article-title":"LSD vs. Alcoholism","volume":"93","author":"McBroom","year":"1968","journal-title":"Sci. News"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fimmu.2015.00358","article-title":"Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities","volume":"6","author":"Szabo","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Wortis, J. (1962). Treatment of Autistic Schizophrenic Children with LSD-25 and UML-491. Recent Advances in Biological Psychiatry, Springer.","DOI":"10.1007\/978-1-4684-8306-2"},{"key":"ref_165","first-page":"43","article-title":"D-lysergic acid in the treatment of the biological features of childhood schizophrenia","volume":"7","author":"Bender","year":"1966","journal-title":"Dis. Nerv. Syst."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archpsyc.1962.01710210019003","article-title":"Autistic Schizophrenic Children; An Experiment in the Use of D-Lysergic Acid Diethylamide (LSD-25)","volume":"6","author":"Freedman","year":"1962","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1520-6807(196407)1:3<297::AID-PITS2310010316>3.0.CO;2-T","article-title":"The treatment of childhood schizophrenia in a public school system","volume":"1","author":"Moller","year":"1964","journal-title":"Psychol. Sch."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF02352266","article-title":"An evaluation of a maximum security therapeutic community for psychopaths and other mentally disordered offenders","volume":"16","author":"Rice","year":"1992","journal-title":"Law Hum. Behav."},{"key":"ref_169","first-page":"283","article-title":"Psychopaths: Is a therapeutic community therapeutic?","volume":"15","author":"Harris","year":"1994","journal-title":"Ther. Communities"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.avb.2013.07.008","article-title":"Reducing psychopathic violence: A review of the treatment literature","volume":"18","author":"Reidy","year":"2013","journal-title":"Aggress. Violent Behav."},{"key":"ref_171","first-page":"303","article-title":"Temporal effects of LSD-25 and epinephrine on verbal behavior","volume":"70","author":"Honigfeld","year":"1965","journal-title":"PsycEXTRA Dataset."},{"key":"ref_172","unstructured":"Weil, G.M., Metzner, R., and Leary, T. (1965). The Treatment of Frigidity with LSD and Ritalin. The Psychedelic Reader: Selected from the Psychedelic Review, University Books. Place of publication not identified."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1503\/cmaj.1150082","article-title":"Psychedelic and nonpsychedelic LSD and Psilocybin for cluster headache","volume":"188","author":"Davenport","year":"2016","journal-title":"Can. Med. Assoc. J."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to Psilocybin and lsd","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"ref_175","unstructured":"Liechti, M., and Schmid, Y. (2021, March 11). Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache (LCH). Identifier NCT03781128. (2 January 2019\u2013December 2023), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03781128."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: Results of the clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"ref_178","first-page":"116","article-title":"Prophylactic treatment of migraine by means of lysergic acid derivatives","volume":"6","author":"Sicuteri","year":"1963","journal-title":"Triangle"},{"key":"ref_179","first-page":"137","article-title":"The prophylactic effect of 1-methyl-D-lysergic acid butanolamide (methysergide) in the treatment of vascular headache. A clinical study","volume":"10","author":"Crowther","year":"1964","journal-title":"Med. Exp. Int. J. Exp. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1526-4610.1977.hed1703118.x","article-title":"Brief report: Phantom limp pain: Sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25)","volume":"17","author":"Fanciullacci","year":"1977","journal-title":"Headache"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1874473708666150107120522","article-title":"A review of lysergic acid diethylamide (LSD) in the treatment of addictions: Historical perspectives and future prospects","volume":"7","author":"Liester","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","article-title":"Psychedelics as medicines for substance Abuse Rehabilitation: Evaluating treatments with lsd, Peyote, ibogaine and Ayahuasca","volume":"7","author":"Winkelman","year":"2015","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/0269881116642542","article-title":"Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy","volume":"30","author":"Amoroso","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_186","unstructured":"(2021, February 16). Psychedelic Drugs Market Projected to Reach $6859.95 Million by 2027. Available online: https:\/\/www.prnewswire.com\/news-releases\/psychedelic-drugs-market-projected-to-reach-6-859-95-million-by-2027--301069861.html."},{"key":"ref_187","unstructured":"(2021, February 16). Europe Psychedelic Drugs Market Global Survey Report with COVID-19 Impact and Overwhelming Hike of BILLION-DOLLAR INDUSTRY: COMPASS, Johnson & JOHNSON, NeuroRX, Hikma Pharmaceuticals, Jazz Pharmaceuticals. Available online: https:\/\/apnews.com\/press-release\/wired-release\/business-technology-lifestyle-products-and-services-mental-health-04591bf30586e804c554fe61fafddaf7."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/02791072.2005.10399803","article-title":"Drug tourism or spiritual healing? Ayahuasca seekers in Amazonia","volume":"37","author":"Winkelman","year":"2005","journal-title":"J. Psychoact. Drugs"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:53:41Z","timestamp":1760136821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":188,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["molecules27082520"],"URL":"https:\/\/doi.org\/10.3390\/molecules27082520","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}